Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ARCHES Final OS Analysis in mHSPC

October 15th 2021

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Dr. Siddiqui on the Current State of Treatment in Nonmetastatic CRPC

October 14th 2021

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.

Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee

October 11th 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Immunotherapy, Second-Generation AR Antagonists Provide Expansive Utility Throughout Prostate Cancer

October 7th 2021

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

Rapid Readouts: ODENZA trial

October 7th 2021

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

FDA Grants Priority Review to 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

September 30th 2021

The FDA has granted a priority review designation to a new drug application for lutetium-177-PSMA-617 for use in the treatment of patients with metastatic castration-resistant prostate cancer following androgen receptor pathway inhibition and taxane-based chemotherapy.

Addition of Olaparib to Abiraterone Improves rPFS in mCRPC

September 24th 2021

Olaparib in combination with abiraterone acetate demonstrated a significant and clinically meaningful improvement in radiographic progression-free survival vs abiraterone alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

FDA Authorizes AI-Based Software to Assist in Prostate Cancer Detection and Diagnosis

September 22nd 2021

The FDA has authorized the marketing of Paige Prostate, an artificial intelligence–based software that was designed to help pathologists scan areas of the body for suspicious cancer as a supplement to the review of digitally-scanned slide images from prostate biopsies.

Nonmetastatic CRPC: Treatment Selection

September 20th 2021

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

Advances in Nonmetastatic CRPC

September 20th 2021

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Nivolumab/Rucaparib Combo Induces Clinically Effective Outcomes in mCRPC Subgroup

September 19th 2021

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets

September 19th 2021

The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

September 18th 2021

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Darolutamide Plus ADT Demonstrates Similar Safety Profile Vs ADT Alone in Nonmetastatic CRPC

September 16th 2021

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC

September 16th 2021

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer

September 15th 2021

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC

September 14th 2021

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Dr. Shore on the Results of the ENACT Trial in Prostate Cancer

September 13th 2021

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.